Center for Biosimilars®
网页Market remonopolization by a biosimilar drug in Poland led to significant price increases for etanercept, resulting in over €3.42 million in excess health care costs, according to a recent study. Sandoz Reports 29% Growth in Biosimilar Revenues for First Half of 2024. By Skylar Jeremias. August 27th 2024.
FDA Approves Pavblu for Retinal Conditions
网页2024年9月17日 · Pavblu was developed by Amgen and comes shortly after the FDA approved Enzeevu (aflibercept-abzv) in August 2024. 2 All 5 aflibercept biosimilars were approved in 2024, beginning with Biocon Biologics's Yesafili (aflibercept-jbvf) and Samsung Bioepis' Opuviz (aflibercept-yszy) in May 2024, followed by Formycon and Klinge Biopharma’s Ahzantive (aflibercept-mrbb) in July 2024 and Enzeevu. 3,4
The Top 5 Biosimilar Articles for the Week of September 16
网页5 天之前 · Here are the top 5 biosimilar articles for the week of September 16, 2024. Number 5: The FDA has approved Pavblu (aflibercept-ayyh), the fifth biosimilar referencing Eylea (aflibercept).1 The new product is approved for the treatment of retinal conditions, including neovascular age-related macular degeneration (wet AMD), macular edema following ...
BioRationality— The Missing Rationality in Biosimilar Discussions …
网页2 天之前 · So, what should be the rational path to making biological drugs more affordable is to reduce biosimilars' cost of goods (COGs). The first element is the media that is commercially supplied at a high premium; we should be able to switch to in-house media using the lowest cost components. Second, switch to …
News - Center for Biosimilars
网页2024年9月9日 · The Economic Impact of Etanercept Biosimilar Remonopolization in Poland. Skylar Jeremias. August 28th 2024. Market remonopolization by a biosimilar drug in Poland led to significant price increases for etanercept, resulting in over €3.42 million in excess health care costs, according to a recent study.
Ophthalmology - Center for Biosimilars
网页2019年10月19日 · Skylar Jeremias. May 20th 2024. The FDA approved the first 2 biosimilars referencing Eylea (aflibercept)—Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy)—for the treatment of ophthalmic conditions. Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth.
The Role of Risk-Sharing Models in Biosimilar Adoption
网页3 天之前 · The risk is financial as opposed to in other treatment areas or newer treatment areas, where the risk is also clinical—for instance, a new monoclonal antibody that gets approved. Ivo Abraham, PhD, RN, University of Arizona Cancer Center, analyzes the need for innovative risk-sharing models to promote biosimilar development and utilization.
Rheumatology - Center for Biosimilars
网页August 29th 2024. The 2023 European Alliance of Associations for Rheumatology (EULAR) recommendations for psoriatic arthritis (PsA) provide an evidence-based treatment strategy, prioritizing conventional and biological disease-modifying antirheumatic drugs, including biosimilars, tailored to disease manifestations, with an emphasis on safety, cost-effectiveness, and patient-centered care.
New Evidence Confirms Safe Biosimilar-to-Biosimilar Switching
网页2024年5月28日 · To add to the current body of evidence, researchers conducted a second search encompassing biosimilar-to-biosimilar switching studies from January 1, 2022, to December 31, 2023. Multiple approaches ensured studies were counted only once, even if outcomes were published in several articles or abstracts. …
Biosimilars Account for 23% Market Share, With Wide Uptake …
网页2024年5月22日 · Despite contributing significantly to reduced drug costs and market growth, biosimilars account for only about 23% of the overall biologics market, showing wide variation in uptake across different molecules, according to the IQVIA Use of Medicines in the US report. This annual trend report aimed to …
- 某些结果已被删除